Mitogen-Activated Protein Kinase 14, antagonists & inhibitors
- Name
- Mitogen-Activated Protein Kinase 14, antagonists & inhibitors
- Accession Number
- DBCAT002783
- Description
Not Available
- Drugs
Drug Drug Description Ralimetinib Ralimetinib has been used in trials studying the treatment of Postmenopausal, Advanced Cancer, Adult Glioblastoma, Fallopian Tube Cancer, and Metastatic Breast Cancer, among others. BMS-582949 BMS-582949 has been investigated for the treatment of Psoriasis. R-1487 Investigated for use/treatment in rheumatoid arthritis. - Drugs & Drug Targets
Drug Target Type R-1487 Mitogen-activated protein kinase 14 target